 |
|
New hope for stroke patients
August 26, 2008Loyola researchers hope to reverse stroke damage by jumpstarting growth of nerve fibers
MAYWOOD, Ill. -- If a stroke patient doesn't get treatment within approximately the first three hours of symptoms, there's not much doctors can do to limit damage to the brain.
But now researchers report a technique that potentially could restore functions to patients weeks or even months after a stroke. The technique involves jumpstarting the growth of nerve fibers to compensate for brain cells destroyed by the stroke.
"In the best-case scenario, this would open up the window of time that people could recover and go back to normal functional status," said Gwendolyn Kartje, MD, Ph.D., a professor in the department of cell biology, neurobiology and anatomy and department of neurology at Loyola University Chicago Stritch School of Medicine in Maywood, Ill. and chief of neuroscience research at Edward Hines Jr. VA Hospital in Hines, Ill.
Kartje and colleagues described the experimental approach, called anti-nogo-A immunotherapy, in a recent review article in the journal Topics in Stroke Rehabilitation.
Anti-nogo has dramatically improved functions in lab animals that have experienced strokes. And an ongoing clinical trial in Europe and Canada is testing anti-nogo in humans who have suffered spinal cord injuries.
Most strokes are caused by clots that block blood flow to one part of the brain, killing brain cells within hours. The drug TPA can minimize damage by dissolving the clot. But TPA is safe and effective only when given within about three hours of the onset of symptoms. Most patients don't receive treatment within that brief window. Patients typically arrive at the hospital too late, or hospitals do not begin administering TPA soon enough.
Anti-nogo is among several new approaches under study that potentially could reverse stroke damage, researchers wrote. Nogo-A is a protein that inhibits the growth of nerve fibers called axons. It serves as a check on runaway nerve growth that could cause a patient to be overly sensitive to pain, or experience involuntary movements. (The protein is called nogo because it in effect says to axons: "No go.") In anti nogo immunotherapy, an antibody disables the nogo protein.
The left side of the brain controls movements on the right side of the body, and vice versa. Thus, a stroke on the left side of the brain can cause paralysis on the right side of the body. In such a patient, anti-nogo would, it's hoped, spur the growth of axons from the healthy right side of the brain. These axons would then grow into the right side of the body and restore functions lost by the stroke.
Anti nogo has been tried on rats that have experienced strokes in old age. As in people, strokes in rats affect one side of the body. Following strokes, the rats were unable to pick up pellets of food with the front paw on the affected side. After anti-nogo, function in this paw was almost completely restored in some rats.
The Swiss pharmaceutical company Novartis is sponsoring a phase 1 clinical trial of anti-nogo for patients paralyzed by spinal cord injuries. Kartje believes anti-nogo also has great potential for stroke patients. A clinical trial for stroke patients could begin as early as 2012, she said. Loyola is among the potential sites for such a trial.
Anti nogo "offers the potential for stroke patients to recover, return to nearly normal functional status, and stay out of nursing homes," Kartje said. "Theoretically, there's no reason why this should not happen."
Loyola University Health System
"In the best-case scenario, this would open up the window of time that people could recover and go back to normal functional status," said Gwendolyn Kartje, MD, Ph.D., a professor in the department of cell biology, neurobiology and anatomy and department of neurology at Loyola University Chicago Stritch School of Medicine in Maywood, Ill. and chief of neuroscience research at Edward Hines Jr. VA Hospital in Hines, Ill.
Kartje and colleagues described the experimental approach, called anti-nogo-A immunotherapy, in a recent review article in the journal Topics in Stroke Rehabilitation.
Anti-nogo has dramatically improved functions in lab animals that have experienced strokes. And an ongoing clinical trial in Europe and Canada is testing anti-nogo in humans who have suffered spinal cord injuries.
Most strokes are caused by clots that block blood flow to one part of the brain, killing brain cells within hours. The drug TPA can minimize damage by dissolving the clot. But TPA is safe and effective only when given within about three hours of the onset of symptoms. Most patients don't receive treatment within that brief window. Patients typically arrive at the hospital too late, or hospitals do not begin administering TPA soon enough.
Anti-nogo is among several new approaches under study that potentially could reverse stroke damage, researchers wrote. Nogo-A is a protein that inhibits the growth of nerve fibers called axons. It serves as a check on runaway nerve growth that could cause a patient to be overly sensitive to pain, or experience involuntary movements. (The protein is called nogo because it in effect says to axons: "No go.") In anti nogo immunotherapy, an antibody disables the nogo protein.
The left side of the brain controls movements on the right side of the body, and vice versa. Thus, a stroke on the left side of the brain can cause paralysis on the right side of the body. In such a patient, anti-nogo would, it's hoped, spur the growth of axons from the healthy right side of the brain. These axons would then grow into the right side of the body and restore functions lost by the stroke.
Anti nogo has been tried on rats that have experienced strokes in old age. As in people, strokes in rats affect one side of the body. Following strokes, the rats were unable to pick up pellets of food with the front paw on the affected side. After anti-nogo, function in this paw was almost completely restored in some rats.
The Swiss pharmaceutical company Novartis is sponsoring a phase 1 clinical trial of anti-nogo for patients paralyzed by spinal cord injuries. Kartje believes anti-nogo also has great potential for stroke patients. A clinical trial for stroke patients could begin as early as 2012, she said. Loyola is among the potential sites for such a trial.
Anti nogo "offers the potential for stroke patients to recover, return to nearly normal functional status, and stay out of nursing homes," Kartje said. "Theoretically, there's no reason why this should not happen."
Loyola University Health System
Stroke Patients Current Events and Stroke Patients News RSSStudy Investigates Non-Surgical Placement of a Gore-tex Type Device in the Heart to Stop Recurrent Strokes and Mini-Strokes
A study is under way at Rush University Medical Center using a small, soft-patch device made of a Gore-tex-type material - often used to make durable outerwear - to close a common hole found in the heart called a patent foramen ovale (PFO) in order to prevent recurrent strokes and transient ischemic attacks (TIAs) in adults.
Dual treatment for stroke leads to improved recovery rates, reduced mortality
It appears that stroke patients who receive both intravenous thrombolysis - a minimally invasive treatment that dissolves abnormal blood clots - and endovascular interventions - such as drugs and implanting medical devices - are much more likely to recover and have lower chances of dying.
Brain implants may help stroke patients overcome partial paralysis
Scientists have shown for the first time that neuroprosthetic brain implants may be able to help stroke patients with partial paralysis.
WVU study demonstrates efficacy of CT perfusion in diagnosis of acute ischemic stroke
A study conducted by a team of stroke experts from West Virginia University Health Sciences Center demonstrates that CT (computed tomography) perfusion imaging - a technology which measures blood flow and is available to most hospitals - may dramatically improve fast and accurate stroke diagnosis, enabling physicians to provide more targeted care and helping avoid potentially life-threatening complications of "clot buster" therapy.
New research could save lives and millions of dollars
The Hunter Medical Research Institute (HMRI) Stroke Research Group has developed a system to fast track stroke treatment which could benefit thousands of Australian stroke patients and save millions of dollars annually.
Treatment window expanded
Patients can still benefit up to 4.5 hours after a stroke if a drug that dis-solves blood clots in the brain is administered. Thus far, three hours had been considered the useful limit for administering thrombolytic drugs.
Telemedicine leads to better stroke treatment decisions
Researchers at the University of California, San Diego Medical Center say that their first-of-its-kind study of a telemedicine program which transports stroke specialists via computer desktop or even laptop to the patient's bedside, using highly sophisticated video, audio and Internet technology, could have an immediate and profound impact on the treatment of stroke patients throughout the world.
Depression after stroke: a neglected problem
People who have had a stroke and the people who are close to them need more support in order to manage the consequences of stroke.
Leukemia drug could save lives of stroke patients
The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the onset of symptoms.
Stroke study reveals key target for improving treatment and suggests that Gleevec may help
For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.
More Stroke Patients Current Events and Stroke Patients News Articles
 | The Stroke Recovery Book: A Guide for Patients and Families by Kip Burkman Are You Recovering from a Stroke? If you or someone you love has had a stroke, you are probably frightened and worried. And, you’re filled with questions. What can be expected in recovery? How much rehabilitation will be needed? No health professional can predict the exact outcome of a stroke. Still, research shows that patients tend to do better when they have supportive families and... |
 | The Stroke Clinician's Handbook: A Practical Guide to the Care of Stroke Patients by Robert N Gan, N Venketasubramanian Ramani There are numerous elaborate and comprehensive textbooks and guidelines on stroke. However, busy clinicians are constantly bombarded with new knowledge for an infinite number of medical conditions. It becomes a challenge for them to tease out the important information that will help guide them through the care of the patient they have right before them. This handbook was thus conceptualized... |
 | Alpha Neurofeedback Training in the Rehabilitation Process of Stroke Patients: An Innovative Approach for a More Effective Treatment of Stroke Patients With Memory Deficits by Herwig Nosko Neurofeedback (NFB) is used in the treatment of a variety of neurological disorders. However, the potential benefit for rehabilitation of stroke patients has not yet been demonstrated. Patients often suffer from severe disturbances of memory and attention related processes, both strongly related to the EEG alpha band.The findings demonstrate the impact of NFB on cognitive performance as well as... |
| Stroke: A Guide for Patients and Their Families by John E. Sarno, Martha Taylor Sarno | |
 | I Need Help: A Stroke Patient's Plea by Helen Underwood Having a stroke can be a devasting experience for both the patient and family. The crisis created by a stroke creates an immediate need for the family to understand how to take care of the stroke patient. "Often the family is upset and disoriented, and leaves the doctor's office without remembering or fully comprehending how to respond properly to the stroke patient's needs." After... |
 | Striking Back at Stroke: A Doctor-Patient Journal by Cleo Hutton, M.D., Louis R. Caplan At age 43, Cleo Hutton awoke to a frightening and completely unfamiliar world. In the prime of life, she experienced a devastating stroke. Suddenly unable to speak, understand, or even walk, Hutton found herself struggling first to survive and then to regain her physical skills and her independence.Striking Back at Stroke is Hutton's personal journal during this trying time, detailing her... |
 | The Aftermath of Stroke: The Experience of Patients and their Families (First Edition) by Robert Anderson Stroke affects the personal, social, professional and family lives of patients and their carers. This book is based on a study in which 175 stroke patients and their family carers were followed from the time of the stroke for a period of eighteen months. It tells of their experience of the illness and examines their patterns of coping, including physical, social, economic and emotional aspects.... |
 | Cognition and Perception in the Stroke Patient: A Guide to Functional Outcomes in Occupational Therapy by Kathleen Okkema Rehabilitation Institute of Chicago, Illinois. The Rehabilitation Institute of Chicago Publication Series. Theoretical and practical information for the evaluation and treatment of cognitive and perceptual problems in stroke... |
| Stroke- It Couldn't Happen to Me: One WomanÆs Story of Surviving a Brain-Stem Stroke (Patient Narratives) by Margaret Cromarty Margaret Cromarty was a nurse who suffered a catastrophic stroke aged just 43, which left her with Locked-In Syndrome. Still paralysed even now, with the aid of an on-screen keyboard she has written this unflinching account of her treatment. It describes the frustrations of being fully aware but ignored as a person by carers unable to communicate effectively, and the painfully slow steps towards... | |
| The Adult Stroke Patient: A Manual for Evaluation and Treatment of Perceptual and Cognitive Dysfunction (Slack/Occupational Therapy) by Barbara Zoltan, Ellen Siev, Brenda Freishtat |
| © 2008 BrightSurf.com |